Accelerated drug development timelines must accommodate all crucial elements of nonclinical safety studies.
Shannon Parisotto
Advertisement
Shannon Parisotto, MBA, is the corporate senior vice president of Charles River Laboratories.
Articles by Shannon Parisotto
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
